ERBB2 and non-small cell lung carcinoma: To study the applicability of the desARE3'UTRERBB2-30 constructs in NSCLC with diverse genetic background, we used HCC827 (EGFR del 19 osimertinib resistant, ERBB2 expressing NSCLC) and NCIH460 (EGFR- and ERBB2-negative KRAS-positive NSCLC) in dose-dependent comparison with standard-of-care trastuzumab deruxtecan (Supplementary Figure 7).